Selectivity of action of typical and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2- aminopropane (DOI)

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 23, Issue 3, 1999, Pages 533-544

  Wettstein, Joseph G ^a   Host, Martine ^b   Hitchcock, Janice M ^a  

^a CNS Research   (United States)

^b SANOFI   (France)

Author keywords

5 HT2; DOI; Dopamine; Hallucinogens; Neuroleptics; Schizophrenia; Serotonin

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 AMINOPROPYL(METHYL)PHOSPHINIC ACID; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPEROZIDE; CITALOPRAM; CLOZAPINE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; ILOPERIDONE; IMIPRAMINE; MORPHINE; NEUROLEPTIC AGENT; NEUROTENSIN RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; REMOXIPRIDE; RISPERIDONE; RITANSERIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SELECTIVITY; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOPHENOL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN AGONISTS; STEREOTYPIC MOVEMENT DISORDER;

EID: 0033121142     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(99)00014-7     Document Type: Article

References (28)

1. αMethyl-Arg-Lys-Pro-Trp-Tle-Leu (NT1). Biochem. Pharmacol., 49: 1147-57.
2. Anderson, J.J., Randall, S. and Chase, TN. (1995): The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride:correlation with extracellular acetylcholine levels in striatum. J. Pharmacol. Exp. Ther., 274: 928-936.
3. Bissette, G. and Nemeroff, C. B. (1995): The neurobiology of neurotensin. In: F.E. Bloom, D.J. Kupfer. (Eds): Psychopharmacology: The Fourth Generation of Progress, pp 573-583, New York: Raven Press.
4. Breier, A. (1995): Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research 14: 187-202.
5. Clark, D. and White, F. J. (1987): Review: D1 dopamine receptor - The search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse, 1: 347-388.
6. 3 antagonists ondansetron, zacopride and MDL-72222. FASEB J., 4: A812.
7. Gaggi R., Dallolio R. and Roncada P. (1997): Effects of the selective 5-HT receptor agonists 8-OH-DPAT and DOI on behavior and brain biogenic amines of rats. Gen. Pharmacol., 28: 583-587.
8. Glennon, R.A. (1986): Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Life Sci., 39: 825-830.
9. Gouret, C.J., Porsolt, R., Wettstein, J.G., Puech, A., Soulard, C. Pascaud, X. and Junien, J.L. (1990): Biochemical and pharmacological evaluation of the novel antidepressant and serotonin uptake inhibitor 2-(3,4-dichlorobenzyl)-2-dimethylamino-1-propanol hydrochloride. Drug Res., 40: 633-640.
10. 2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol. Behav. Brain Res., 88: 43-49.
11. 2A Antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther., 277: 968-981.
12. 2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology 118: 178-182.
13. Leikin, J.B., Krantz, A.J., Zell-Kanter, M., Barkin, R.L., and Hrykorczuk, D.O. (1989): Clinical features and management of intoxication due to hallucinogenic drugs. Med. Toxicol. & Adver. Drug Exper., 4(5): 324-50.
14. McKenna, D.J., Nazarali, A.J., Hoffman, A.J., Nichols, D.E., Mathis, C.A. and Saavedra, J.M. (1989). Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125]LSD and [125]DOI, a new psychotomimetic radioligand. Brain Research. 476: 45-56.
15. Miller, P.L., Gay, G.R., Ferris, K.C., and Anderson, S. (1992): Treatment of acute, adverse psychedelic reactions: "I've tripped and I can't get down". J. Psychoact. Drugs. 24(3): 277-9.
16. Pazos, A.., Probst, A. and Palacios, J.M. (1987): Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience, 21: 123-139.
17. 1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI). Neurosci. Lett., 115: 74-80.
18. Sanchez, C. and Meier, E. (1997): Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129: 197-205.
19. Sannerud, C.A. and Young, A.M. (1987): Environmental modification of tolerance to morphine discriminative stimulus properties in rats. Psychopharmacology 93: 59-68.
20. 2A receptors in antipsychotic activity. Life Sci., 56: 2209-2222.
21. 1A agonists. J. Pharmacol. Exp. Ther., 273: 101-112.
22. Schreiber, R., Brocco, M. and Millan, M.J. (1994): Blockade of the discriminative stimulus effects of DOI by M100907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur. J. Pharmacol., 264: 99-102.
23. Shulgin, A.T. (1982). Chemistry of Psychotomimetics. In: Hoffmeister F., Stille G. (Eds), pp 3-29, Handbook of Experimental Pharmacology, Vol 55, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs, Berlin, Springer-Verlag.
24. B receptors on neurones in rat brain slices. Brit. J. Pharmacol., 101: 949-957
25. Sarhan, S., Hitchcock, J.M., Grauffel, C.A. and Wettstein, J.G. (1997): Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides, 18: 1223-1227.
26. 2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur. J. Pharmacol., 102: 23-29.
27. 2 receptor antagonist M100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther., 266: 684-691.
28. Wettstein, J.G. and Gauthier, B. (1992): Discriminative stimulus effects of alprazolam and diazepam: generalization to benzodiazepines, antidepressants and buspirone. Behav. Pharmacol. 3: 229-237.